摘要
目的 探讨舒利迭联合孟鲁司特治疗咳嗽变异性哮喘患者气道炎症的影响。方法 选择2015年3月至2016年3月我院诊治的咳嗽变异性哮喘患者70例作为研究对象。按随机数表法分为观察组和对照组各35例。对照组采用舒利迭进行治疗，观察组在对照组的基础上联合孟鲁司特进行治疗。比较两组患者的症状改善用时情况、肺通气功能、促炎症细胞因子水平、嗜酸性粒细胞（Eosinophil，Eos）及呼出气一氧化氮（Fractional exhaled nitric oxide, FeNO）水平。结果 治疗后，观察组症状缓解和消失用时均短于对照组[（6.05±1.44）d比（7.21±1.52）d，（7.63±1.75）d比（8.74±1.58）d] （P〈0.05）；观察组患者肺通气功能中第1秒用力呼气容积（FEV1）、第1秒用力呼气容积占预计值百分比（FEV1/pred）、第1秒用力呼气容积占用力肺活量比值（FEV1/FVC）及呼气峰流速占预计值百分比（PEF/pred）均高于对照组（P〈0.05）；观察组的白细胞介素（interleukin，IL）-12高于对照组[（84.26±10.97） ng/L比（68.13±9.82） ng/L] （P〈0.05），肿瘤坏死因子α（tumour necrosis factor-α，TNF-α）及IL-6均低于对照组[（0.65±0.13） ng/L比（0.94±0.16） ng/L，（14.11±3.78）ng/L比（20.43±4.14）ng/L] （P〈0.05）；观察组患者的Eos及FeNO均低于对照组[（2.61±1.75）%比（5.34±2.03）%，（45.68±11.43）ppb比（78.46±18.42）ppb] （P〈0.05）。结论 舒利迭联合孟鲁司特治疗咳嗽变异性哮喘能有效改善患者肺通气功能，缩短治疗时间，缓解患者气道炎症并改善患者的炎症反应状态，效果显著，值得推广。
Objective To study the curative efficacy of Montelukast combined with Seretide for the treatment of cough variant asthma （CVA） and its effect on airway inflammation.Methods 70 patients of CVA, who received therapy from March 2015 to March 2016 in our hospital, were selected as research objects.According to random number table, those patients were divided into the observation group and the control group, with 35 patients in each group.The control group was treated with Seretide, while the observation group was treated with Montelukast combined with Seretide.The duration in which the symptom of the patients was improved after treatment, pulmonary ventilation function, proinflammatory cytokine levels, eosinophil （Eos）, and fractional exhaled nitric oxide （FeNO） were compared.Results After treatment, the duration for symptom relief and disappearance of the observation group were shorter than that of the control group[（6.05±1.44）d vs（7.21±1.52）d, （7.63±1.75）d vs（8.74±1.58）d]（P〈0.05）. The FEV1, FEV1/pred, FEV1/FVC and PEF/pred were significantly higher in the observation group than those in the control group（P〈0.05）. The level of interleukin（IL）-12 in the observation group was higher than that in the control group [（84.26±10.97） ng/L vs（68.13±9.82）ng/L]（P〈0.05）. The tumor necrosis factor-α （TNF-α） and IL-6 were lower than those in the control group [（0.65±0.13） ng/L vs（0.94±0.16） ng/L, （14.11±3.78）ng/L vs（20.43±4.14）ng/L] （P〈0.05）. The Eos and FeNO in the observation group were lower than those in the control group [（2.61±1.75）% vs （5.34±2.03）%, （ 45.68±11.43） ppb vs （78.46±18.42） ppb] （P〈0.05）.Conclusion The treatment of cough variant asthma with the combination of Sulidide and montelukast can effectively improve patients with pulmonary ventilation function, and it shorted the treatment time, relieved airway inflammation and improved the patient＇s inflammatory response.
作者
陈亮
李天林
Li Tianlin Chen Liang(Department of Respiration, Xia Men Chang Gung Hospital, Xiamen 361000, China)
出处
《国际免疫学杂志》
CAS
2017年第5期510-514,共5页
International Journal of Immunology
